Predictions in Real-World Evidence for 2021: Bridging the Organizational Gaps

bridging-the-organizational-gaps
By Jeff Trotter, Senior Vice President, Scientific Solutions, Real-World Evidence,

  In the past year, we have witnessed a tangible shift in the clinical research community with respect to the application of real-world evidence (RWE) and real-world data (RWD) in drug development and commercialization. As we prepare to harness the potential of RWE and RWD to advance business opportunities for our sponsors and to improve healthcare for patients, life sciences companies must identify areas for growth and refinement in this space. To help us identify opportunities and trends, Jeff Trotter, Senior Vice President, Scientific Solutions, Real-World Evidence, is sharing his predictions for developments in RWE and RWD for the year ahead. This is the final installment in Jeff Trotter’s five-part blog series: Predictions in Real-World Evidence for 2021.

Read More

Predictions in Real-World Evidence for 2021: Improved Strategic Foundation for RWE

real-world-evidence-strategy-predictions
By Jeff Trotter, Senior Vice President, Scientific Solutions, Real-World Evidence,

  In the past year, we have witnessed a tangible shift in the clinical research community with respect to application of real-world evidence (RWE) and real-world data (RWD) in drug development and commercialization. As we prepare to harness the potential of RWE and RWD to advance business opportunities for our sponsors and to improve healthcare for patients, life sciences companies must identify areas for growth and refinement in this space. To help us identify opportunities and trends, Jeff Trotter, Senior Vice President, Scientific Solutions, Real-World Evidence, is sharing his predictions for developments in RWE and RWD for the year ahead. This is the fourth in Jeff Trotter’s five-part blog series: Predictions in Real-World Evidence for 2021.

Read More

Regulatory Affairs: Five Predictions for 2021

regulatory-affairs-predictions
By Aman Khera, Global Head of Regulatory Strategy,

  This past year has been extraordinary for each one of us, and our industry has taken center stage. As the world looks to clinical research to bring the threat of COVID-19 under control, the regulatory affairs space has become a focus of scrutiny, both from within the industry and from the world at large. Recently, Worldwide Clinical Trials conducted a poll of industry leaders, asking them to prioritize their key areas of focus for 2021. It is unsurprising that patient recruitment is an ongoing concern, while other emerging areas of focus are technology, data harmonization, and transparency. As we move into 2021, I’d like to offer my predictions for the regulatory space.

Read More